Rokos Capital Management (UK)’s Intellia Therapeutics NTLA Stock Holding History

Rokos Capital Management (UK)’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,140,973	Closed	-$25.5M	–	106
2024 Q2	$25.5M	Sell	1,140,973 -322,657	-22%	-$7.68M	0.16%	53
2024 Q1	$40.2M	Hold	1,463,630	–	–	0.21%	42
2023 Q4	$44.6M	Buy	1,463,630 +74,334	+5%	+$2.14M	0.39%	30
2023 Q3	$44.3M	Hold	1,389,296	–	–	0.32%	38
2023 Q2	$56.5M	Hold	1,389,296	–	–	0.55%	27
2023 Q1	$51.6M	Buy	1,389,296 +563,233	+68%	+$22.1M	3.82%	8
2022 Q4	$28.4M	Buy	826,063 +535,535	+184%	+$25.5M	1.24%	18
2022 Q3	$16.7M	Sell	290,528 -41,856	-13%	-$2.6M	0.5%	42
2022 Q2	$16.8M	Buy	332,384 +220,869	+198%	+$11.2M	0.49%	39
2022 Q1	$8.08M	Buy	+111,515	New	+$9.45M	0.38%	39

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rokos Capital Management (UK)'s NTLA Position: Q3 2024 in Review

Rokos Capital Management (UK) sold out of Intellia Therapeutics (NTLA) in Q3 2024, closing a stake of 1,140,973 shares — an estimated $25.5M sold.

Rokos Capital Management (UK) first reported a position in NTLA in Q1 2022 and held it in 10 quarters. The position peaked at $56.5M in Q2 2023. 284 funds tracked by Wall St. Rank hold NTLA as of Q3 2024.

Rokos Capital Management (UK) reported no remaining Intellia Therapeutics position as of Q3 2024 after selling out during the quarter.
Rokos Capital Management (UK) sold 1,140,973 Intellia Therapeutics shares in Q3 2024, an estimated $25.5M.
Rokos Capital Management (UK) first reported a position in Intellia Therapeutics in Q1 2022 and held it in 10 quarters.
Rokos Capital Management (UK)'s Intellia Therapeutics position peaked at $56.5M in Q2 2023.
284 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2024.

Based on Rokos Capital Management (UK)'s 13F filing for Q3 2024, filed 14 Nov 2024.